AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)
13F holders, Q1 2026 (March 31)1holders
$0.00avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger) in their 13F filings. The largest holder was Trium Capital LLP ($0).
- Company
- AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)
- CUSIP
- G29CVR019
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Trium Capital LLP | 0.00% | New | 1,292,985 | $0 |
"% of holder's portfolio" is AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger)'s weight in each manager's 13F, not the share of AVADEL PHARMACEUTICALS CVR (ALKERMES PLC merger) the manager owns.